Sigyn Therapeutics – Blood Purification Technology to Treat Cytokine Storm

Jim Joyce, co-founder, chairman, and CEO of Sigyn Therapeutics discusses the development of Sigyn Therapy, the company’s blood purification technology to overcome the limitations of drugs and other devices to treat Cytokine Storm induced inflammatory conditions that lead to sepsis. He explains the relationship between Cytokine Storm and COVID and how this blood purification technology is an approach that is getting alot of attention right now. He talks about how this technology differs from current blood purification technologies and what the current treatment landscape looks like. 

Read More

Saniona – FDA Orphan Drug Designation for Tesomet in Hypothalamic Obesity

Rami Levin, President and CEO of Saniona discusses Tesomet, the first and only investigational treatment for Hypothalamic Obesity (HO) to receive orphan drug designation. This marks a major milestone for the patient community as there are currently no medications specifically approved for HO. Patients living with this disease experience uncontrollable hunger and intractable weight gain, which is often complicated by depression, impulse control issues and increased risk of cardiovascular and metabolic disorders. This milestone builds on the orphan drug designation granted by the FDA earlier this year to Tesomet for the treatment of Prader-Willi Syndrome (PWS) and Saniona is preparing to initiate Phase 2b studies of Tesomet in HO and PWS in the second half of this year.​ 

Read More

The Asthma Toolkit Bootcamp – Bridging the Gap Between Urban and Rural Healthcare

Dr. Bruce Bender, PhD, lead researcher and co-director of the Center for Health Promotion at National Jewish Health discusses recent research published in “The Journal of Allergy and Clinical Immunology: In Practice” about The Asthma Toolkit Bootcamp, a program that improved physician adherence to current guidelines, leading to fewer hospitalizations, emergency room visits, and decreased use of oral medications. 

Read More

Personal Growth and Healing After Trauma

Daniel Shapiro, author of “The Thin Ledge: A Husband’s Memoir of Love, Trauma, and Unexpected Circumstances” shares the reality of the fifteen years he spent living and caring for his wife, who suffered two massive brain hemorrhages and a personality change, while also single handedly raising their three young children. He discusses moving on and growing from trauma, moral issues, the struggle of a caregiver, and his perspective as a male caregiver. This book addresses questions that people living through unspeakable misfortunes may never mention, but almost always ask. ​​

Read More

AAIC 2021 – Prothena – Alzheimer’s Vaccine Data and Next-Gen Alzheimer’s Treatment Data

Hideki Garren, MD, PhD, Chief Medical Officer at Prothena discusses data from two presentations at the Alzheimer’s Association International Conference (AAIC); PRX012, Prothena’s next generation anti-amyloid beta (Aβ) antibody and the dual Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer’s Disease (AD).   He talks about the company’s approach to addressing the AD global healthcare crisis.  

Read More

3 Ways to Increase Productivity, Improve Patient Engagement and Reduce Burnout

Returning guest, Cathy Kuhn, PharmD, Director, Voice of the Customer at Updox, a complete healthcare communication platform for in-person and virtual care, discusses their recently released “Paperless Practice Playbook” with tips for providers on how to increase productivity, improve patient engagement and reduce burnout. She talks about why providers must eliminate paper in order to reduce the amount of time spent on administrative tasks for both provider and patients and how one practice saved more than 500 hours a year on administrative tasks by leveraging a paperless practice. 

Read More

First Presentation of Long-Term Safety & Efficacy Data for Dengue Vaccine Candidate

Derek Wallace, Vice President and Dengue Global Program Lead at Takeda, discusses the first public presentation of long-term safety and efficacy results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate, TAK-003, and the launch of the company’s global HCP dengue education platform, Dengue Academy

Read More